Trial description
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA)
Contact name
Dr Danish Mazhar
Trial start date
Tuesday, September 24, 2019
Trial end date
Wednesday, December 30, 2020
Trial tumour type
Show on Radiotherapy